The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis

DSpace/Manakin Repository

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis

Citable link to this page

 

 
Title: The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
Author: Dupuy, Sheena L.; Khalid, Fariha; Healy, Brian C.; Bakshi, Sonya; Neema, Mohit; Tauhid, Shahamat; Bakshi, Rohit

Note: Order does not necessarily reflect citation order of authors.

Citation: Dupuy, Sheena L., Fariha Khalid, Brian C. Healy, Sonya Bakshi, Mohit Neema, Shahamat Tauhid, and Rohit Bakshi. 2016. “The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.” BMC Medical Imaging 16 (1): 56. doi:10.1186/s12880-016-0158-4. http://dx.doi.org/10.1186/s12880-016-0158-4.
Full Text & Related Files:
Abstract: Background: Spinal cord atrophy occurs early in multiple sclerosis (MS) and impacts disability. The therapeutic effect of interferon beta-1a (IFNβ-1a) on spinal cord atrophy in patients with relapsing-remitting (RR) MS has not been explored. Methods: We retrospectively identified 16 consecutive patients receiving weekly intramuscular IFNβ-1a for 2 years [baseline age (mean ± SD) 47.7 ± 7.5 years, Expanded Disability Status Scale score median (range) 1.5 (0–2.5), timed 25-foot walk 4.6 ± 0.7 seconds; time on treatment 68.3 ± 59.9 months] and 11 sex- and age-matched normal controls (NC). The spinal cord was imaged at baseline, 1 and 2 years later with 3T MRI. C1-C5 spinal cord volume was measured by an active surface method, from which normalized spinal cord area (SCA) was calculated. Results: SCA showed no change in the MS or NC group over 2 years [mean annualized difference (95 % CI) MS: −0.604 mm2 (−1.352, 0.144), p = 0.106; NC: −0.360 mm2 (−1.576, 0.855), p = 0.524]. Between group analysis indicated no differences in on-study SCA change [MS vs. NC; year 1 vs. baseline, mean annualized difference (95 % CI) 0.400 mm2 (−3.350, 2.549), p = 0.780; year 2 vs. year 1: −1.196 mm2 (−0.875, 3.266), p = 0.245; year 2 vs. baseline −0.243 mm2 (−1.120, 1.607), p = 0.712]. Conclusion: Established IFNβ-1a therapy was not associated with ongoing spinal cord atrophy or any difference in the rate of spinal cord volume change in RRMS compared to NC over 2 years. These results may reflect a treatment effect. However, due to sample size and study design, these results should be considered preliminary and await confirmation.
Published Version: doi:10.1186/s12880-016-0158-4
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053209/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:29408411
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters